Experience

ABL

• Russian Federation
• Spectator Sports

• Responsable Développement des procédés & Innovation

  • Jun 2023 - Present

• Viral Vector Manufacturing & Process Development Specialist

  • Feb 2020 - Jul 2023

  • Lead the AAV program of ABL-Europe ( USP/DSP platform development)• Manage and coordinate Process development team • Coordinate production teams for Viral Vector GMP manufacturing up to 200L scale. • Lead the experimental design and oversee upstream and downstream technical teamsfor the development of small-scale process (up to 50L) and qualified scaled down models for AAV and other type of viral vector production• Write, review, and approve manufacturing batch records. • Collect, assemble, analyse and summarise production data• Review executed batch records, change controls, deviations, investigations• Participate in manufacturing investigations in collaboration with other departments • Work with QA, QC, CMC project management and other departments to advanceprojects• Review of technical documents related to Health Authority submissions Show less



Cell and Gene Therapy Catapult

• United Kingdom
• Biotechnology Research
• 200 - 300 Employee

• Senior Scientist | Viral Vector Industrialisation

  • Aug 2019 - Feb 2020

• Process Development - Viral Vector Scientist

  • Jun 2018 - Aug 2019

  • Delivery of Viral Vector process (AAV and LV) and analytical development projects.• Particular focus upon Downstream process operations, including unit operations from harvest to final fill.• Perform, develop and optimize Viral Vector purification methods using filtration and chromatography methods.• Strong Interaction with academic and industry-based groups to provide engineering solutions for vector cell line development, Upstream and Downstream bioprocessing.• Assist with costing of proposals for partners and support of BD function during new project scoping by providing technical support activities.• Write and Review SOPs in relation to Viral Vectors projects.• Contribute to the smooth running of the laboratory, helping to ensure effective lab management. Show less



Imperial College London

• Research Services
• 700 & Above Employee

• Research Associate

  • Feb 2013 - May 2018

  As a Senior Postdoctoral researcher in the Allday lab my role was to understand the mechanisms by which the human tumour virus Epstein-Barr Virus causes human B cells to proliferate. My research focused on the EBNA3 proteins of EBV which play key roles in cell transformation and some cancers caused by this virus. EBNA3A and EBNA3C are involved in the repression of important tumour suppressive pathways, they are required for efficient B cell transformation, they play a role in the attenuation of the DNA damage response and are considered oncogenic. I developed molecular biology techniques and created new conditional cell lines that have been used in different studies and have already proved to be powerful tools for the analysis of EBNA3 functions. I also developed lentiviral vectors platform carrying shRNA or gene of interest as well as vectors delivering CRISPR/Cas9 components to perform genome editing. Show less



Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 – ENS de Lyon

• Ph.D student

  • Oct 2008 - Dec 2012

  During my PhD I have worked under the supervision of Dr Evelyne Manet on the characterization of protein interaction networks involved in cell transformation by the Epstein-Barr Virus (EBV). My goal was to study and investigate the interactions between viral proteins and the human proteome in order to get a better understanding of the role of these viral proteins during B-lymphocytes immortalization process by EBV. My work was focus on the EBNA3 protein family (EBNA3A, EBNA3B and EBNA3C) and on the EBNA1 protein. The EBNA3s are nuclear multifunctional proteins essential for progression through the cell cycle. EBNA1 is absolutely required for DNA replication and maintenance of the EBV episomal genome through cell divisions. Show less